Jowy Yi Hoong Seah, Wee Siong Chew, Federico Torta, Chin Meng Khoo, Markus R Wenk, Deron R Herr, Hyungwon Choi, E Shyong Tai, Rob M van Dam
{"title":"血浆鞘脂与心血管疾病风险:大规模脂质组学分析","authors":"Jowy Yi Hoong Seah, Wee Siong Chew, Federico Torta, Chin Meng Khoo, Markus R Wenk, Deron R Herr, Hyungwon Choi, E Shyong Tai, Rob M van Dam","doi":"10.1007/s11306-020-01709-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sphingolipids are a diverse class of lipids with various roles in cell functions and subclasses such as ceramides have been associated with cardiovascular diseases (CVD) in previous studies.</p><p><strong>Objectives: </strong>We aimed to measure molecularly-distinct sphingolipids via a large-scale lipidomic analysis and expand the literature to an Asian population.</p><p><strong>Methods: </strong>We performed a lipidomics evaluation of 79 molecularly distinct sphingolipids in the plasma of 2627 ethnically-Chinese Singaporeans.</p><p><strong>Results: </strong>During a mean follow-up of 12.9 years, we documented 152 cases of major CVD (non-fatal myocardial infarction, stroke and cardiovascular death). Total ceramide concentrations were not associated with CVD risk [hazard ratio (HR), 0.99; 95% CI 0.81-1.21], but higher circulating total monohexosylceramides (HR, 1.22; 95% CI 1.03, 1.45), total long-chain sphingolipids (C16-C18) (HR, 1.22; 95% CI 1.02, 1.45) and total 18:1 sphingolipids (HR, 1.21; 95% CI 1.01, 1.46) were associated with higher CVD risk after adjusting for conventional CVD risk factors.</p><p><strong>Conclusions: </strong>Our results do not support the hypothesis that higher ceramide concentrations are linked to higher CVD risk, but suggest that other classes of sphingolipids may affect CVD risk.</p>","PeriodicalId":144887,"journal":{"name":"Metabolomics : Official journal of the Metabolomic Society","volume":" ","pages":"89"},"PeriodicalIF":0.0000,"publicationDate":"2020-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11306-020-01709-8","citationCount":"13","resultStr":"{\"title\":\"Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis.\",\"authors\":\"Jowy Yi Hoong Seah, Wee Siong Chew, Federico Torta, Chin Meng Khoo, Markus R Wenk, Deron R Herr, Hyungwon Choi, E Shyong Tai, Rob M van Dam\",\"doi\":\"10.1007/s11306-020-01709-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Sphingolipids are a diverse class of lipids with various roles in cell functions and subclasses such as ceramides have been associated with cardiovascular diseases (CVD) in previous studies.</p><p><strong>Objectives: </strong>We aimed to measure molecularly-distinct sphingolipids via a large-scale lipidomic analysis and expand the literature to an Asian population.</p><p><strong>Methods: </strong>We performed a lipidomics evaluation of 79 molecularly distinct sphingolipids in the plasma of 2627 ethnically-Chinese Singaporeans.</p><p><strong>Results: </strong>During a mean follow-up of 12.9 years, we documented 152 cases of major CVD (non-fatal myocardial infarction, stroke and cardiovascular death). Total ceramide concentrations were not associated with CVD risk [hazard ratio (HR), 0.99; 95% CI 0.81-1.21], but higher circulating total monohexosylceramides (HR, 1.22; 95% CI 1.03, 1.45), total long-chain sphingolipids (C16-C18) (HR, 1.22; 95% CI 1.02, 1.45) and total 18:1 sphingolipids (HR, 1.21; 95% CI 1.01, 1.46) were associated with higher CVD risk after adjusting for conventional CVD risk factors.</p><p><strong>Conclusions: </strong>Our results do not support the hypothesis that higher ceramide concentrations are linked to higher CVD risk, but suggest that other classes of sphingolipids may affect CVD risk.</p>\",\"PeriodicalId\":144887,\"journal\":{\"name\":\"Metabolomics : Official journal of the Metabolomic Society\",\"volume\":\" \",\"pages\":\"89\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s11306-020-01709-8\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Metabolomics : Official journal of the Metabolomic Society\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11306-020-01709-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Metabolomics : Official journal of the Metabolomic Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11306-020-01709-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13
摘要
鞘脂是一类在细胞功能中具有多种作用的脂类,在以往的研究中,神经酰胺等亚类与心血管疾病(CVD)有关。目的:我们旨在通过大规模脂质组学分析来测量分子上不同的鞘脂,并将文献扩展到亚洲人群。方法:我们对2627名新加坡华人血浆中79种分子上不同的鞘脂进行了脂质组学评估。结果:在平均12.9年的随访期间,我们记录了152例主要CVD(非致死性心肌梗死、中风和心血管死亡)。总神经酰胺浓度与CVD风险无关[危险比(HR), 0.99;95% CI 0.81-1.21],但较高的循环总单己糖神经酰胺(HR, 1.22;95% CI 1.03, 1.45),总长链鞘脂(C16-C18) (HR, 1.22;95% CI 1.02, 1.45)和总鞘脂含量18:1 (HR, 1.21;95% CI 1.01, 1.46)在调整常规心血管疾病危险因素后与较高的心血管疾病风险相关。结论:我们的研究结果不支持高神经酰胺浓度与高心血管疾病风险相关的假设,但表明其他类型的鞘脂可能影响心血管疾病风险。
Plasma sphingolipids and risk of cardiovascular diseases: a large-scale lipidomic analysis.
Introduction: Sphingolipids are a diverse class of lipids with various roles in cell functions and subclasses such as ceramides have been associated with cardiovascular diseases (CVD) in previous studies.
Objectives: We aimed to measure molecularly-distinct sphingolipids via a large-scale lipidomic analysis and expand the literature to an Asian population.
Methods: We performed a lipidomics evaluation of 79 molecularly distinct sphingolipids in the plasma of 2627 ethnically-Chinese Singaporeans.
Results: During a mean follow-up of 12.9 years, we documented 152 cases of major CVD (non-fatal myocardial infarction, stroke and cardiovascular death). Total ceramide concentrations were not associated with CVD risk [hazard ratio (HR), 0.99; 95% CI 0.81-1.21], but higher circulating total monohexosylceramides (HR, 1.22; 95% CI 1.03, 1.45), total long-chain sphingolipids (C16-C18) (HR, 1.22; 95% CI 1.02, 1.45) and total 18:1 sphingolipids (HR, 1.21; 95% CI 1.01, 1.46) were associated with higher CVD risk after adjusting for conventional CVD risk factors.
Conclusions: Our results do not support the hypothesis that higher ceramide concentrations are linked to higher CVD risk, but suggest that other classes of sphingolipids may affect CVD risk.